Published • loading... • Updated
Hyundai Bioscience says XAFTY cuts H1N1 by 99.2% in human lung organoids
Summary by News Article Insiders
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Hyundai Bioscience says XAFTY cuts H1N1 by 99.2% in human lung organoids
Pictured above is the logo of Hyundai Bioscience. The firm says that its broad-spectrum antiviral drug candidate XAFTY demonstrated a 99.2 percent reduction in influenza A viral replication in a human lung alveolar organoid model. [Photo courtesy of Hyundai Bioscience] South Korea’s Hyundai Bioscience announced on July 30 that its broad-spectrum antiviral drug candidate XAFTY demonstrated a 99.2 percent reduction in influenza A (H1N1) viral repl…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
